How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
New White Paper: Speeding up Patient Access to Innovation: Strategies to Convert Early European Regulatory Approval Into Optimal Reimbursement
Efforts to facilitate patient access to innovative medicines have taken on new urgency in the pandemic era, sharpening drug developers’ focus on the first step in this process: securing regulatory approval.
New White Paper: Gene Therapies in Hemophilia
Multiple curative gene therapies for hemophilia are getting closer to the market, but in the days of restricted affordability how do we ensure that these life-changing therapies will be able to get in the hands of the patient that need them most?
New White Paper: The Future of Reimbursement for Cell and Gene Therapies
Payer concerns over cell and gene therapies have long been focused around the uncertainty of their long-term benefits... However, with their effectiveness proven, and the prices of treatments continuing to rise, how will they react next?
